CUE
Cue Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CUE Profile
Cue Biopharma, Inc.
A clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body
Biological Technology
12/31/2014
01/02/2018
NASDAQ Stock Exchange
41
12-31
Common stock
40 Guest Street, Boston, MA 02135
--
Cue Biopharma, Inc., was incorporated in Delaware on December 31, 2014. The company is a clinical-stage biopharmaceutical company that designs a new class of injectable therapies to selectively directly participate in and regulate targeted, disease-associated T cells in patients. The company's vision is to translate nature's signals, or "cues," into protein therapies by generating a new class of T-cell conjugants for the selective regulation of disease-specific T-cells.
